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Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with
bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia. Zoledronic
acid, the most frequently used intravenous agent, has been traditionally administered on a monthly
dosing schedule. Preclinical studies have demonstrated that zoledronic acid can inhibit angiogenesis,
invasion, and adhesion of tumor cells. Several clinical studies of different timings and schedules of zo-
ledronic acid therapy have demonstrated its anti-tumor effects, as well as its protective effect on bone
health, in postmenopausal women during adjuvant breast cancer therapy. In general, early initiation of
zoledronic acid, concomitantly with adjuvant therapy, has been found to be most beneﬁcial. However,
questions remain over the most effective schedule of treatment and relative potency of zoledronic acid.
Therefore, we review the existing clinical studies to examine the inﬂuence of dosing of zoledronic acid
therapy on clinical outcomes in patients with breast cancer.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The bone is the most common site of tumor metastasis, in
about 20–25% of cancer patients [1]. Bone metastases are most
common from carcinomas of the breast, lung, prostate, kidney, and
thyroid. Some bone metastases are osteoclastic, whereas others
are osteoblastic or mixed, resulting from reactive bone formation.
Zoledronic acid (Zometa, Novartis) is the only bisphosphonate
indicated for the management of solid tumors with bone metas-
tases at the time of writing [2]. It is about 100–1000 times more
potent than other bisphosphonates such as clodronate, pami-
dronate, risedronate, alendronic acid, or etidronate [3–13]. Zole-
dronic acid inhibits farnesyl diphosphate synthase, an enzyme in
the mevalonate pathway, reducing the post-translational pre-
nylation of proteins such as small GTPases, and resulting in the
disruption of metabolic pathways essential for cancer cell survival
[3,14]. Zoledronic acid may also exert indirect anti-tumor effects
by modulating the immune system. It is structurally similar to
low-molecular-weight, non-peptide compounds with a phosphate
residue, which is recognized by gamma delta T cells in the med-
iation of immune responses directed against tumor cells [3].
Several dosing schedules of zoledronic acid for the treatment of
osteoporosis and bone metastases have been proposed [15,16].
Several dosing schedules of zoledronic acid have been studied,
including conventional dosing (4 mg intravenously every 3–4GmbH. This is an open access artweeks), maintenance dosing (4 mg intravenously every 3–6
months), and metronomic dosing (1 mg intravenously weekly).
Different dosing schedules may have different anti-tumor effects.2. Conventional dosing
Zoledronic acid has been demonstrated in vitro and in vivo to
have anti-tumor activity. Although the approved dosing schedules
of zoledronic acid (4 mg intravenously every 3–4 weeks) and pa-
midronate (90 mg intravenously monthly) have reduced the risk of
skeletal morbidity in patients with bone metastases, the anti-tu-
mor activity of zoledronic acid in breast cancer patients still needs
to be optimized.
Levels of circulating vascular endothelial growth factor (VEGF),
an critical biomarker of tumor angiogenesis, may be useful in the
optimization of bisphosphonate use. Increased levels of circulating
VEGF correlate with poor prognosis and negative clinical out-
comes, including shortened survival, in multiple tumor types.
Furthermore, preclinical studies have demonstrated that bispho-
sphonates are able to inhibit angiogenesis. Promising data from
2 clinical studies in patients with metastatic bone disease de-
monstrated that a single dose of zoledronic acid (4 mg) or pami-
dronate (90 mg) can reduce levels of circulating VEGF. In patients
with bone metastases from late-stage solid tumors, circulating
VEGF levels were analyzed after monthly treatment with zole-
dronic acid [16]. VEGF levels decreased 7 days after zoledronic acid
infusion [16]. Similarly, in breast cancer patients with bone me-
tastases (N¼42), zoledronic acid signiﬁcantly reduced basal VEGFicle under the CC BY-NC-ND license
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reductions correlated with delayed time to bone disease progres-
sion (58 versus 34 weeks; p¼0.0024) and delayed time to ﬁrst
skeleton related events (SRE) (76 versus 39 weeks; p¼0.0002)
compared with patients whose VEGF levels remained elevated.
Zoledronic acid has been clinically evaluated for potential anti-
angiogenic effects in patients with bone metastases from advanced
cancers [15]. In patients who received zoledronic acid, circulating
levels of VEGF decreased after 1 week (p¼0.04) [15]. This inhibi-
tion persisted throughout the 84-day observation period of the
study (pr0.014). Since changes in levels of serum VEGF correlated
with clinical outcomes, zoledronic acid-mediated suppression of
serum VEGF levels may decrease tumor burden in patients with
advanced and metastatic cancers. The anti-tumor activity of con-
ventional zoledronic acid was also assessed in a study of patients
with multiple myeloma (N¼94) who were randomized to receive
standard anti-cancer therapy with or without a conventional
(4 mg monthly) dose of zoledronic acid [18]. Patients who received
zoledronic acid had signiﬁcantly improved progression free sur-
vival (PFS) (20% versus 48%; po0.01), event-free survival (80%
versus 52%; po0.01), and overall survival (OS) (80% versus 46%;
po0.01) compared with patients who received only anticancer
therapy, as well as a reduction in the incidence of skeletal-related
events [18]. Since all patients received the same anti-cancer
treatment in the same setting, the improved clinical results of
zoledronic acid-containing regimen were attributed to the anti-
tumor activity of zoledronic acid. Preliminary clinical data re-
garding the anti-tumor activity of conventional setting of zole-
dronic acid are encouraging, but further analyses are required to
conﬁrm the optimal treatment setting.3. Bone half-life based dosing
As zoledronic acid has been shown to have anti-tumor efﬁcacy
in both the pre-clinical and clinical settings using the conventional
regimen (zoledronic acid 4 mg infusion 4 weekly), some studies
were designed to explore the anti-tumor effects of zoledronic acid
when administered continuously every 6 months. In ABSCG-12,
1803 premenopausal women that compares the efﬁcacy and safety
of anastrozole or tamoxifen with or without zoledronic acid (4 mg
every 6 months) for 3 years. At a median follow-up of 62 months,
Zoledronic acid (4 mg every 6 months) with adjuvant endocrine
therapy signiﬁcantly improved DFS versus endocrine therapy
without zoledronic acid (92% versus 88%, respectively; log-rank
p¼0.008). This 4% absolute difference in DFS corresponded to a
signiﬁcant reduction in the relative risk of events for patients re-
ceiving versus not receiving zoledronic acid, stratiﬁed by endo-
crine therapy (76 versus 110 events; HR 0.68, 95% conﬁdence in-
terval [CI] 0.51–0.91, Cox p¼0.009, log-rank p¼0.008). Zoledronic
acid signiﬁcantly reduced the relative risk of DFS events both in
node-positive (HR 0.67, 95% CI 0.45–0.99) and node-negative pa-
tients (HR 0.66, 95% CI 0.43–1.03). Fewer patients receiving zole-
dronic acid had distant disease recurrence at both bone and non-
bone sites (44 versus 56 events), including contralateral breast
cancer (6 versus 8 events) and locoregional recurrence (15 versus
30 events). In a subgroup analysis by patient age at study entry, a
treatment by-covariate interaction based on patients aged 40 years
or younger versus those older than 40 years did not reveal sig-
niﬁcant heterogeneity (p¼0.121). However, in patients who were
40 years or younger at baseline (N¼413), zoledronic acid did not
signiﬁcantly reduce the relative risk of DFS events (HR 0.94, 95% CI
0.57–1.56), whereas in those who were older than 40 years at
study entry (N¼1390), the risk reduction with in patients treated
with zoledronic acid was signiﬁcant (HR 0.58, 95% CI 0.40–0.83).
Thirty deaths (3% of 900 patients) occurred in the zoledronic acidgroup, whereas 43 deaths (5% of 903 patients) occurred in the
non-zoledronic acid group; risk of death did not differ signiﬁcantly
between these groups (HR 0.67, 95% CI 0.41–1.07; Cox p¼0.09). OS
also did not differ signiﬁcantly between treatment groups in pa-
tients with node-positive (HR 0.62, 95% CI 0.34–1.15) and node-
negative disease (HR 0.70, 95% CI 0.33–1.52). The addition of zo-
ledronic acid improved DFS in patients taking either anastrozole or
tamoxifen. These data show consistent beneﬁts with zoledronic
acid and support its addition to adjuvant endocrine therapy in
premenopausal patients with early-stage breast cancer [19].
In the ZO-FAST study, 1065 women were randomly assigned to
immediate zoledronic acid 4 mg every 6 months for 5 years, or
delayed zoledronic acid. Patients were administered letrozole for a
median of approximately 60 months. After 5 years of follow-up,
patients in the immediate-zoledronic acid group had a 34% relative
reduction in the risk of DFS events versus the delayed-zoledronic
acid group, HR 0.66, 95% CI 0.44–0.97, p¼0.0375). Fewer local and
distant disease recurrences occurred in the immediate-zoledronic
acid group versus the delayed-zoledronic acid group (local re-
currences, 0.9% versus 2.3%, respectively; distant recurrences, 5.5%
versus 7.7%, respectively). Bone metastases were more common in
the delayed-zoledronic acid group versus the immediate-zole-
dronic acid group (4.5% versus 2.6%, respectively). Contralateral
breast cancers were reported in 3 patients in the immediate-zo-
ledronic acid group versus 6 in the delayed-zoledronic acid group.
Immediate use of zoledronic acid substantially improved DFS
versus patients in the delayed arm (HR 0.62, 95% CI 0.41–0.93;
p¼0.0239). Exploratory analyses showed that zoledronic acid in-
itiation in this group (N¼144) improved DFS versus no zoledronic
acid treatment (HR 0.46, p¼0.0334). A larger (non-signiﬁcant)
proportion of patients initiating delayed zoledronic acid treatment
were lymph node-positive at diagnosis (70%) compare to those not
initiating delayed zoledronic acid (55%), which may contribute to
an underestimate of the DFS beneﬁts from delayed introduction of
zoledronic acid. Other prognostic factors identiﬁed for DFS in the
delayed-zoledronic acid arm included tumor stage (HR 2.16,
p¼0.0416 for ZT2 versus T0 or T1) and age (HR 1.95, p¼0.0236
for age Z65 versus o65 years). Further exploratory analyses
showed trends towards improved DFS with immediate zoledronic
acid in recently menopausal (N¼177) and truly postmenopausal
(N¼888) patients (0.05opo0.1). In exploratory analyses of wo-
men with established postmenopausal status (45 years post-
menopausal or 460 years of age at study entry; N¼670), im-
mediate zoledronic acid was associated with a trend for improved
DFS (HR 0.63, p¼0.0516) and demonstrated substantially im-
proved OS (HR 0.50, p¼0.0224) versus delayed zoledronic acid.
These ﬁndings show that, in addition to improving bone health,
initiating zoledronic acid immediately may improve DFS compared
with delaying zoledronic acid [20].
In the phase 3 AZURE trial, 3360 women were randomly as-
signed to receive standard adjuvant systemic treatment alone
(control group) or with 4 mg intravenous zoledronic acid every 3–
4 weeks for 6 doses, then every 3 months for 8 doses, followed by
every 6 months for 5 doses, for a total of 5 years of treatment. The
number of DFS events did not differ between the 2 groups. DFS,
OS, and distant recurrences were also similar in both groups.
However, zoledronic acid reduced the development of bone me-
tastases, both as a ﬁrst event (HR 0.78, 95% CI 0.63–0.96; p¼0.020)
and at any time during follow-up (HR 0.81, 95% CI 0.68–0.97;
p¼0.022). The effects of zoledronic acid on DFS were not affected
by estrogen receptor (ER) status. However, zoledronic acid im-
proved IDFS in those who were over 5 years since menopause at
trial entry (N¼1041; HR 0.77, 95% CI 0.63–0.96) but not in all other
(premenopause, perimenopause, and unknown status) menopau-
sal groups (N¼2318; HR 1.03, 95% CI 0.89–1.20). For post-
menopausal women with stage II or III breast cancer, the absolute
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rate of 1–2% suggest a favorable risk-to-beneﬁt ratio. Overall, these
data do not support the use of adjuvant zoledronic acid in un-
selected patients with early breast cancer. However, these data
suggest that zoledronic acid can be used for postmenopausal
women with early breast cancer who are receiving adjuvant
treatment [21,22].
Recently, a meta-analysis on 18,766 women with median fol-
low-up 5.6 years showed that by using bisphosphonates including
zoledronic acid, the reductions in recurrence (RR 0. 94, 95% CI
0.87–1.01; 2p¼0.08), distant recurrence (0.92, 0.85–0.99;
2p¼0.03), and breast cancer mortality (0.91, 0.83–0.99; 2p¼0.04)
were of only borderline signiﬁcance, but the reduction in bone
recurrence was more signiﬁcant (0.83, 0.73–0 94; 2p¼0.004).
Even for bone recurrence, however, the heterogeneity of beneﬁt
was barely signiﬁcant by age (2p¼0.03) and menopausal status
(2p¼0.06 for trend with menopausal status), and it was non-sig-
niﬁcant by bisphosphonate class, treatment schedule, estrogen
receptor status, nodes, etc. No differences were seen in non-breast
cancer mortality. Bone fractures were reduced (RR 0.85, 95% CI
0.75–0.97; 2p¼0.02). Hence, adjuvant bisphosphonates including
zoledronic acid was able to reduce the rate of breast cancer re-
currence in the bone and improve breast cancer survival, but there
is signiﬁcant beneﬁt only in postmenopausal women [23].4. Blood half-life based use
On the basis of promising data from an in vivo study suggesting
that low-dose weekly regimens of zoledronic acid were able to
reduce skeletal tumor burden, Santini et al. designed a study to
explore the potential anti-angiogenic effect of a weekly low-dose
therapy with zoledronic acid in patients with malignancies.
Twenty-six patients with solid cancer and bone metastases were
administered 1 mg of zoledronic acid weekly for 4 times followed
by 4 mg of zoledronic acid over a standard 4-week schedule, re-
peated 3 times. The median VEGF basal level showed a statistically
signiﬁcant (p¼0.038) decrease 7 days after the ﬁrst 1 mg dose of
zoledronic acid, and this effect persisted after 1 mg infusions at 14
(p¼0.002), 21 (p¼0.001), and 28 days (p¼0.008). Moreover, the
decrease in circulating VEGF levels persisted at each prespeciﬁed
time point during the second phase of the study (zoledronic acid
4 mg every 4 weeks) [24].
Based on these preliminary clinical results with low-dose, in-
termittent zoledronic acid, Hu et al. conducted a randomized
phase II clinical study in order to clarify the role of metronomic
low-dose zoledronic acid. Sixty breast cancer patients with bone
metastases were randomized to receive either 1 mg intravenous
zoledronic acid weekly for 4 doses, or a single 4 mg intravenous
dose of zoledronic acid. Administration of other treatments was
delayed for 1 month. Serial blood samples were collected on days
1, 15, 29, and at 3 months. Serum VEGF alteration was the primary
endpoint. Compared to the conventional arm, the metronomic arm
exhibited a signiﬁcantly greater reduction in serum levels of VEGF
and N-telopeptide of type I collagen (NTx) during the ﬁrst month
of treatment. Serum CA 15-3 level stabilized over time in the
metronomic arm, but increased in the conventional arm. In-
dependent prognostic factors for PFS included chemotherapy re-
ceived (HR 8.042, p¼0.000), ER status (HR 2.837, p¼0.020), VEGF
levels at 3 months after intervention (HR 2.026, p¼0.045), and
baseline NTx (HR 1.051, p¼0.001). This is the ﬁrst study to de-
monstrate that metronomic weekly low-dose zoledronic acid
could be more effective than the conventional zoledronic acid
dosing schedule. The weekly regimen resulted in more effective
suppression of circulating VEGF and NTx levels, and possibly, more
effective stabilization of serum tumor markers. Intervention-related VEGF levels at 3 months after zoledronic acid treatment
are an independent prognostic factor for PFS. Further evaluation of
the clinical and biomarker parameters of the metronomic (q
1 week) zoledronic acid regimen is clearly warranted [24].
Therefore, the prognostic and predictive effects of clinical and
biochemical factors were examined in the aforementioned ran-
domized study of a weekly low dose (metronomic arm) versus a
conventional dosage of zoledronic acid (conventional arm) in
breast cancer patients with bone metastases. Speciﬁcally, treat-
ment outcomes in 60 patients with bone metastases were used to
assess the impacts of the following potential prognostic factors: ER
status, lymph node status, 2-year disease-free interval (DFI),
numbers of chemotherapy regimens administered, interventions,
serum levels of VEGF, NTx, CEA, and CA 15-3. In univariate ana-
lyses, patients pretreated with 2 or fewer chemotherapy regimens,
patients with ER-positive tumors, patients with 3 or fewer lymph
nodes, patients with DFI of more than 2 years, patients with serum
VEGF of less than 500 pg/mL after 3 months of intervention, pa-
tients with serum CEA and CA 15-3 of less than ULN, and patients
with baseline serum NTx of less than 18 nM BCE had signiﬁcantly
longer PFS. Multivariate analysis showed that ER positivity (HR
0.295; 95% CI 0.141–0.618, p¼0.001), serum VEGF of less than
500 pg/mL after 3 months of intervention (HR 2.220, 95% CI 1.136–
4.338, p¼0.020), baseline serum NTx of less than 18 nM BCE (HR
2.842, 95% CI 1.458–5.539, p¼0.001), and 2 or fewer chemother-
apy regimens received (HR 7.803, 95% CI 2.884–21.112, p¼0.000)
were associated with better PFS. When evaluating the predictive
effect of the biochemical factors, an interaction between NTx and
zoledronic acid intervention was shown (p¼0.005). The HR of
weekly low dose versus conventional zoledronic acid dosage was
estimated to be 2.309 (99% CI 1.067–5.012) in patients with
baseline serum NTx of more than 18 nM BCE. In conclusion, these
results indicate superiority of weekly low dose of zoledronic acid
over conventional dosing. ER, serum VEGF level after intervention,
and numbers of chemotherapy regimens administered are prog-
nostic but not predictive factors in breast cancer patients with
bone metastases. Patients with baseline serum NTx of more than
18 nM BCE might beneﬁt more from weekly low-dose of zole-
dronic acid [26]. Clinical results with low-dose, intermittent zo-
ledronic acid are consistent with those observed in animal models,
providing a rationale for further investigations of alternative
dosing regimens to optimize the anti-tumor potential of zole-
dronic acid.5. Biomarker-driven dosing
Bone turnover biomarkers offer an avenue to evaluate the on-
going rate of skeletal metabolism and interactions between cancer
and skeleton in patients. The mutual effect between cancer and
bone decouples activities spatially and disturbs otherwise ba-
lanced activities resulting in elevated rates of osteolysis and os-
teogenesis. During this process high levels of distinct biochemical
markers are released into blood or urine that are amenable to non-
invasive detection [24]. Bone metabolism biochemical markers can
provide meaningful evidence that tumor growth inﬂuences on-
going bone turnover rate. Such biochemical markers include cross-
linked collagen peptides broken from osteolysis, (e.g. the amino
[N]- and carboxy [C]-terminal cross-linked telopeptides of type I
collagen [NTX and CTX]) and the terminal peptides cleaved from
procollagen before its incorporation into newly synthesized bone
matrix (e.g. procollagen type I N-terminal and C-terminal peptides
[PINP and PICP]). Serum CTX and the urinary NTX are correlated
with the ongoing osteolysis rates, whereas serum bone-speciﬁc
alkaline phosphatase (bone ALP) and PINP are correlated with the
ongoing osteogenesis rates [24]. Bone metabolism marker such as
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osteogenesis. In general, bone metabolism biochemical markers
connect with the ongoing rates of osteolysis and osteogenesis.
Bone marker level variation is not disease speciﬁc, and is in-
dependent of the underlying cause of skeletal metabolism altera-
tion [25]. Metabolism biochemical markers, on the whole, may not
predict speciﬁc lesion site. Emerging evidence suggests that bone
markers are helpful in identifying patients with high risk of bone
metastasis and bone lesion progression [24,25]. Potential appli-
cation of bone metabolism biochemical markers should be eval-
uated in clinical trials to identify the true value in clinical practice
[27,28].6. Future research and challenges
The utility of zoledronic acid as adjuvant or neoadjuvant ther-
apy for its anti-tumor effects in breast cancer is currently being
investigated in several clinical trials, including SWOG S0307,
SUCCESS, and Natan. SWOG S0307 is a trial of bisphosphonates as
adjuvant therapy for primary breast cancer. The main purpose of
this phase III trial is to study the efﬁcacy of zoledronic acid com-
pared with clodronate or ibandronate in treating women who
have undergone surgery for stage I, stage II, or stage III breast
cancer. The primary endpoints are DFS and OS, assessed every
6 months for the ﬁrst 5 years and then annually for 5 years, or
until death or recurrence. The study was designed to enroll 5400
patients.
SUCCESS A and C are randomized, open-label, 22 factorial
design phase III studies in patients with high-risk of breast cancer
(stage N1, or T2–T4, or grade 3, or age r35 years, or hormone-
receptor negative). The aim of this study is to evaluate the pre-
dictive value of zoledronic acid treatment on the prevalence of
CTCs at 5 years after primary diagnosis, in addition to other well-
known predictors. Patients were ﬁrst randomized to adjuvant
chemotherapy treatment with 3 cycles of FEC, followed by either
3 cycles of docetaxel (SUCCESS A), or 3 cycles of gemcitabine-
docetaxel (SUCCESS C). In addition, patients were randomized to
2 years versus 5 years of zoledronic acid treatment. Very recently,
it has been shown that zoledronic acid treatment duration has no
effect on the prevalence of CTCs 5 years after primary diagnosis
from 2014 SABCS. However, the same results also conﬁrmed that
CTCs may persist after standard adjuvant therapy. Immediately
after Ctx, CTCs seem to be more prevalent in patients with HER2-
positive tumors compared with other molecular subtypes. Other
trials in this setting may provide additional information on the
predictive role of CTCs in the context of bisphosphonate treatment.
The Natan study is comparing neoadjuvant therapy with or
without zoledronic acid, and is a study that we are following
closely. It is a randomized, multicenter, open-label phase III study
comparing the postoperative use of zoledronic acid with no
postoperative treatment in patients with histological tumor re-
siduals after preoperative anthracycline and taxane-containing
chemotherapy for primary breast cancer. The primary endpoint is
5-year event-free survival from the time of postoperative
treatment.
Data from these studies will provide important insights into the
anti-tumor effects of zoledronic acid, especially in postmenopausal
breast cancer patients. We believe that more studies should be
designed in this population to further explore suitable dosing and
duration of zoledronic acid therapy, and to further understand its
mechanisms of action.
7. Conclusions
In addition to its effects on BMD and bone remodeling,zoledronic acid has potent anti-tumor effects. These are related to
its dosing schedule and to patient factors, such as the low estrogen
environment in post-menopausal breast cancer patients. Four-
weekly or 6-monthly administration of this agent can improve the
prognosis of cancer patients, while a 1 mg weekly low-dose may
have stronger anti-tumor effects. However, these hypotheses need
to be evaluated by further clinical studies.References
[1] H.L. ABRAMS, R. SPIRO, N. GOLDSTEIN, Metastases in carcinoma; analysis of
1000 autopsied cases, Cancer 3 (1) (1950) 74–85.
[2] A. Osborne, Zoledronic acid, Clin. J. Oncol. Nurs. 6 (6) (2002) 365–366.
[3] T.A. Guise, Antitumor effects of bisphosphonates: promising preclinical evi-
dence, Cancer Treat. Rev. 34 (Suppl 1) (2008) S19–S24.
[4] A. Lipton, Emerging role of bisphosphonates in the clinic–antitumor activity
and prevention of metastasis to bone, Cancer Treat. Rev. 34 (Suppl 1) (2008)
S25–S30.
[5] P.D. Ottewell, et al., Antitumor effects of doxorubicin followed by zoledronic
acid in a mouse model of breast cancer, J. Natl. Cancer Inst. 100 (16) (2008)
1167–1178.
[6] E.F. Solomayer, et al., Inﬂuence of zoledronic acid on disseminated tumor cells
in primary breast cancer patients, Ann. Oncol. 23 (9) (2012) 2271–2277.
[7] E. Giraudo, M. Inoue, D. Hanahan, An amino-bisphosphonate targets MMP-9-
expressing macrophages and angiogenesis to impair cervical carcinogenesis, J.
Clin. Invest. 114 (5) (2004) 623–633.
[8] M.F. Gnant, et al., Zoledronic acid prevents cancer treatment-induced bone
loss in premenopausal women receiving adjuvant endocrine therapy for hor-
mone-responsive breast cancer: a report from the Austrian Breast and Color-
ectal Cancer Study Group, J. Clin. Oncol. 25 (7) (2007) 820–828.
[9] M. Gnant, et al., Endocrine therapy plus zoledronic acid in premenopausal
breast cancer, N. Engl. J. Med. 360 (7) (2009) 679–691.
[10] A. Brufsky, et al., Integrated analysis of zoledronic acid for prevention of ar-
omatase inhibitor-associated bone loss in postmenopausal women with early
breast cancer receiving adjuvant letrozole, Oncologist 13 (5) (2008) 503–514.
[11] R.E. Coleman, Adjuvant bisphosphonates in breast cancer: are we witnessing
the emergence of a new therapeutic strategy? Eur. J. Cancer 45 (11) (2009)
1909–1915.
[12] R.T. Chlebowski, et al., Oral bisphosphonate use and breast cancer incidence in
postmenopausal women, J. Clin. Oncol. 28 (22) (2010) 3582–3590.
[13] G. Rennert, M. Pinchev, H.S. Rennert, Use of bisphosphonates and risk of
postmenopausal breast cancer, J. Clin. Oncol. 28 (22) (2010) 3577–3581.
[14] J.E. Kim, et al., Zoledronic acid prevents bone loss in premenopausal women
with early breast cancer undergoing adjuvant chemotherapy: a phase III trial
of the Korean Cancer Study Group (KCSG-BR06-01), Breast Cancer Res. Treat.
125 (1) (2011) 99–106.
[15] D. Santini, et al., Repeated intermittent low-dose therapy with zoledronic acid
induces an early, sustained, and long-lasting decrease of peripheral vascular
endothelial growth factor levels in cancer patients, Clin. Cancer Res. 13 (2007)
4482–4486 15 Pt 1.
[16] D. Santini, et al., Pamidronate induces modiﬁcations of circulating angioge-
netic factors in cancer patients, Clin. Cancer Res. 8 (5) (2002) 1080–1084.
[17] B. Vincenzi, et al., Zoledronic acid-related angiogenesis modiﬁcations and
survival in advanced breast cancer patients, J. Interferon Cytokine Res. 25 (3)
(2005) 144–151.
[18] A. Aviles, et al., Antitumor effect of zoledronic acid in previously untreated
patients with multiple myeloma, Med. Oncol. 24 (2) (2007) 227–230.
[19] M. Gnant, et al., Adjuvant endocrine therapy plus zoledronic acid in pre-
menopausal womenwith early-stage breast cancer: 62-month follow-up from
the ABCSG-12 randomised trial, Lancet Oncol. 12 (7) (2011) 631–641.
[20] R. Coleman, et al., Zoledronic acid (zoledronate) for postmenopausal women
with early breast cancer receiving adjuvant letrozole (ZO-FAST study): ﬁnal
60-month results, Ann. Oncol. 24 (2) (2013) 398–405.
[21] R. Coleman, et al., Adjuvant zoledronic acid in patients with early breast
cancer: ﬁnal efﬁcacy analysis of the AZURE (BIG 01/04) randomised open-label
phase 3 trial, Lancet Oncol. 15 (9) (2014) 997–1006.
[22] K. Harnden, K. Blackwell, Routine use of zoledronic acid in early-stage breast
cancer, J. Natl. Compr. Cancer Netw. 13 (4) (2015) 480–486.
[23] Adjuvant bisphosphonate treatment in early breast cancer, meta-analyses of
individual patient data from randomised trials, Lancet (2015).
[24] D. Santini, et al., Repeated intermittent low-dose therapy with zoledronic acid
induces an early, sustained, and long-lasting decrease of peripheral vascular
endothelial growth factor levels in cancer patients, Clin. Cancer Res. 13 (15)
(2007) 4482–4486.
[25] X. Zhao, et al., Biomarker alterations with metronomic use of low-dose zole-
dronic acid for breast cancer patients with bone metastases and potential
clinical signiﬁcance, Breast Cancer Res. Treat. 124 (3) (2010) 733–743.
[26] X. Zhao, et al., Prognostic and predictive value of clinical and biochemical
factors in breast cancer patients with bone metastases receiving “me-
tronomic” zoledronic acid, BMC Cancer 11 (2011) 403.
[27] J.R. Gralow, et al., NCCN task force report: bone health in cancer care, J. Natl.
Compr. Cancer Netw. 11 (Suppl 3) (2013), S1-50; quiz S51.
[28] R. Coleman, et al., Bone health in cancer patients: ESMO clinical practice
guidelines, Ann. Oncol. 25 (suppl 3) (2014) iii124–iii137.
